I-Flow's InfuSystem joins HAPC:
This article was originally published in Clinica
Executive Summary
Chemotherapy infusion pump service provider InfuSystem has taken on a new name, InfuSystem Holdings, following the closing of its sale to HAPC. New York-based HAPC had initially agreed to buy InfuSystem from the latter's parent company, I-Flow, in October 2006 for $140m, but the sale price was reduced to $100m in September this year to reflect changes in the economic environment and the marketplace, said the companies (see Clinica No 1274, p 11). I-Flow will also receive $12m in milestones as part of the deal. The Lake Forest, California firm had bought a 15% stake in HAPC in October to push through shareholder approval of the transaction.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.